

**31<sup>st</sup> October 2014**

## **ASX ANNOUNCEMENT**

### **APPENDIX 4C - QUARTERLY CASH FLOW**

Analytica Limited (the Company) please find attached the Appendix 4C for the quarter ended 30<sup>th</sup> September 2014.

Following the end of the September quarter the Company has raised additional funds of \$850k via a placement at 3 cents per share with Paterson's Securities Limited as well as having closed a 1 for 8 entitlement offer at 3 cents per share raising \$2.56m.

The Company also received a \$989k tax incentive rebate.

The receipt of these funds brings cash on hand as at 30 October to \$4.4 million.

During the September operating cash outflows were \$1.1m comprising research and development expenditure (\$454k), staff costs (\$367k), marketing expenses (\$71k) and other operating working capital (\$250k).

The investor presentation attached to the entitlement offer (released 14<sup>th</sup> October available on [analyticamedical.com](http://analyticamedical.com) or [asx.com.au](http://asx.com.au)) updates the progress achieved in the September quarter. With the imminent release of the enhanced Pericoach system, the company enjoys a stronger cash position for this transition from research and development to marketing.

The Company continues to have access to a line of credit of \$400k.

**Dr Michael Monsour**

Chairman, Board of Directors



## *About Analytica Limited*

*Analytica's lead product is the PeriCoach™ System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.*

*PeriCoach™ comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is correctly performing pelvic floor exercises and if these are improving her condition; otherwise physicians are guided on the need for surgery.*

*PeriCoach™ has been approved in Australia with product launches expected in 2014 in Australia, and Europe and the US in 2015. The US market for incontinence pads is \$5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence. The product is not available for sale in the USA.*

*Analytica is also commercialising the AutoStart™ Infusion System. This is a burette with improved safety and cost reduction features. It is targeting a \$3 billion pa global market, has FDA approval and potential near term cash flow with distribution agreements.*

# Appendix 4C

## Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Analytica Limited

ABN

12 006 464 866

Quarter ended ("current quarter")

30/09/2014

### Consolidated statement of cash flows

Cash flows related to operating activities		Current quarter \$A'000	Year to date (3 months) \$A'000
1.1	Receipts from customers		
1.2	Payments for		
	(a) staff costs	(367)	(367)
	(b) advertising and marketing	(71)	(71)
	(c) research and development	(454)	(454)
	(d) leased assets	-	-
	(e) other working capital	(250)	(250)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	7	7
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Other-		
	(a) Net sales income	1	1
	(b) R & D Tax Concession	-	-
	(c) Royalty Income	-	-
	(d) Other Grant Income	-	-
<b>Net operating cash flows</b>		<b>(1,134)</b>	<b>(1,134)</b>

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

	Current quarter \$A'000	Year to date (3 months) \$A'000
1.8 Net operating cash flows (carried forward)	(1,134)	(1,134)
<b>Cash flows related to investing activities</b>		
1.9 Payment for acquisition of:		
(a) businesses	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	(19)	(19)
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (purchase of Convertible Notes )	-	-
<b>Net investing cash flows</b>	(19)	(19)
<b>1.14 Total operating and investing cash flows</b>	<b>(1,153)</b>	<b>(1,153)</b>
<b>Cash flows related to financing activities</b>		
1.15 Proceeds from issues of shares	(2)	(2)
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings:	-	-
1.19 Dividends paid	-	-
1.20 Other Creditors (costs of fund raising)	(9)	(9)
<b>Net financing cash flows</b>	(11)	(11)
<b>Net increase (decrease) in cash held</b>	<b>(1,164)</b>	<b>(1,164)</b>
1.21 Cash at beginning of quarter/year to date	1,947	1,947
1.22 Exchange rate adjustments to item 1.20	-	-
<b>1.23 Cash at end of quarter</b>	<b>783</b>	<b>783</b>

+ See chapter 19 for defined terms.

**Payments to directors of the entity and associates of the directors**

**Payments to related entities of the entity and associates of the related entities**

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	38
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions <div style="border: 1px solid black; padding: 5px; margin-top: 5px;">           Payment of director's fees and compulsory superannuation.         </div>	

**Non-cash financing and investing activities**

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

**Financing facilities available**

*Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).*

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities	400	0
3.2 Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

### Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	783	1,947
4.2	Deposits at call	-	-
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
<b>Total: cash at end of quarter</b> (item 1.23)		783	1,947

### Acquisitions and disposals of business entities

	Acquisitions	Disposals
5.1	Name of entity	N/A
5.2	Place of incorporation or registration	
5.3	Consideration for acquisition or disposal	
5.4	Total net assets	
5.5	Nature of business	

### Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:      Original signed

Date: 31 October 2014

Print name:      Bryan Dulhunty (Company Secretary)

---

+ See chapter 19 for defined terms.